Technically Oversold with Support Solid Patents & A Heavyweight Board: Is This Stock Set to Soar? Arch Biopartners Inc (ARCH:TSXV; ACHFF:OTCQB) is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The companys...

📰 Streetwise Reports featured Arch Biopartners in a contributed technical analyst opinion discussing the company’s kidney-focused pipeline and recent public disclosures.

🔗 Read the full report here: www.streetwisereports.com/article/2026...

#ArchNews #BiotechNews

News Release - January 16, 2026 - Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

🚨 Arch Biopartners announced the appointment of Dr. Patrick Vink, M.D., M.B.A., as Chairman of the Board, effective January 15, 2026. Dr. Vink brings extensive experience in global pharmaceutical leadership and governance.

📖 Full release:
archbiopartners.com/investor-hub

#ArchBiopartners #ArchNews

News release headline, clinical trial update from Arch Biopartners, August 6, 2025. Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury

Arch Biopartners’ CS-AKI Phase II clinical trial is now active at Toronto General Hospital, ranked Canada's #1 and #3 globally.

First patient dosed in the trial at this leading cardiac research hospital.

🔗 dub.sh/first-patien...

#ArchBiopartners #CSAKI #AKI #LSALTpeptide #clinicaltrials #ArchNews

Arch Biopartners Company Logo, and stock tickers (ARCH: TSX.V, and ACHFF: OTCQB). Headline, July 22, 2025 Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)

🚨 Arch Biopartners now has two lead drug candidates in active Phase II trials:

🔹 Cilastatin: in the PONTIAK trial for drug-toxin-related AKI, now open for recruitment
🔹 LSALT peptide: cardiac surgery-associated AKI

🔗 archbiopartners.com/investor-hub...

#AKI #Cilastatin #LSALTpeptide #ArchNews

Contact Us – Arch Biopartners

📢 Long-format versions of Arch's posts are shared on LinkedIn (dub.sh/arch-linkedin).

Bluesky posts are mirrored on X (@archbiopartners).

Please follow, like and share to help expand reach.

📧 Prefer email? Subscribe here: archbiopartners.com/contact-us

#ArchBiopartners #InvestorFAQ #ArchNews

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) – Arch Biopartn...

🚨 (22 April 2025) Arch Biopartners announced that UHN-TGH (Toronto General Hospital) is prepared to begin recruiting subjects for the Phase II trial of LSALT peptide for CS-AKI.

📖 Full release at – dub.sh/arch-uhn-tgh...

#AKI #CSAKI #KidneyCare #LSALTpeptide #ArchBiopartners #DPEP1 #ArchNews